Taltz ® (ixekizumab) injection

80 mg/mL

The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.

TALTZ® (ixekizumab): Drug Holiday in Plaque Psoriasis

Taltz prescribing information does not contain recommendations for drug holiday. With consistent dosing, most patients maintained response at Week 60.

Drug Holiday in Plaque Psoriasis



  • TALTZ® prescribing information does not contain recommendations for drug holidays in patients treated with ixekizumab. With consistent dosing, most patients maintained response at week 60 (Taltz Package Insert, 2017).


  • Data on stopping ixekizumab treatment after 12 weeks following clinical response, then re-starting after relapse, are described below. For these analyses, Response was defined as a static Physician Global Assessment (sPGA) score of 0 (clear) or 1(minimal) and Relapse was defined as a sPGA score of >3 (Taltz Package Insert, 2017).


  • Seventy-five percent of patients who responded ([sPGA] 0,1) to ixekizumab (every 2 weeks [Q2W]) at week 12 and were then re-randomized to an additional 48 weeks of ixekizumab 80 mg every 4 weeks (Q4W) consistently maintained their response at week 60 (Taltz Package Insert, 2017).


  • Conversely, for responders to ixekizumab Q2W at week 12 who were then re-randomized to treatment withdrawal (ie, placebo), the median time to relapse was about 5 months. Following relapse and then re-starting on ixekizumab 80mg Q4W, 66% regained their response within 12 weeks (Taltz Package Insert, 2017).


  • The analyses were conducted from UNCOVER-1 and UNCOVER-2 Phase 3 clinical trials. Details regarding the study designs for both the 12-week induction and 48-week maintenance periods of the phase 3 UNCOVER Clinical Trials are illustrated in Appendix A, Figure 1 (Taltz Package Insert, 2017).


Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

Reference

Taltz® [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.




Additional related information

Date of Last Review: February 20, 2017

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a question

Visit Us @LillyMedical